GlassScriptPhysician profile
David G Stoddard
NPI 1629398706
$9,504.53
in general payments reported to CMS, 2019-2025
18 companies · $420 in 2025
The $420 reported for 2025 was less than what a typical Otolaryngic Allergy provider received nationally (typical 2025 total: $449).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,506 · 2020: $694 · 2021: $715 · 2022: $999 · 2023: $1,832 · 2024: $3,339 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,950 · Food and Beverage: $1,785 · Travel and Lodging: $856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,950.00 |
| Food and Beverage | $1,784.62 |
| Travel and Lodging | $855.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $3,459.49 | 2021-2024 | Dupixent |
| Aerin Medical INC. | $1,776.35 | 2022-2025 | |
| Intersect Ent, INC. | $895.81 | 2019-2022 | |
| Stryker Corporation | $877.75 | 2019-2025 | Audion Et Dilation System |
| Astrazeneca Pharmaceuticals LP | $528.14 | 2021-2025 | Tezspire |
| Inspire Medical Systems, INC. | $506.84 | 2019-2022 | |
| Genzyme Corporation | $458.47 | 2019-2025 | |
| Medtronic USA, INC. | $262.49 | 2019-2020 | |
| Arrinex, INC. | $238.19 | 2019 | |
| Glaxosmithkline, LLC. | $178.87 | 2022-2025 | Nucala |
| Neurent Medical Limited | $98.97 | 2024-2025 | Neuromark Radiofrequency Console, Neuromark Device, Neuromark System |
| Medtronic, INC. | $74.20 | 2022 | |
| Optinose US, INC. | $52.98 | 2020 | |
| Alk-Abello, INC | $28.63 | 2023 | Standardized Mite D. Farinae, Timothy, Standardized, Alternaria Tenuis |
| Regeneron Healthcare Solutions, INC. | $27.52 | 2019-2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axogen | $26.14 | 2022 | |
| Kaleo, INC. | $13.69 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Stoddard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.